1. The Role of Circulating Tumor DNA in Ovarian Cancer.
- Author
-
Golara, Anna, Kozłowski, Mateusz, and Cymbaluk-Płoska, Aneta
- Subjects
- *
METHYLATION , *OVARIAN tumors , *CHROMOSOME abnormalities , *TUMOR markers , *TREATMENT effectiveness , *CANCER chemotherapy , *METASTASIS , *NUCLEIC acids , *HORMONE therapy , *EXTRACELLULAR space , *GENETIC mutation , *TUMOR classification , *BODY fluids - Abstract
Simple Summary: The diagnosis and treatment of ovarian cancer still pose many problems; so, it is important to search for effective biomarkers that will allow for the detection of changes in the early stages of the disease. There is more and more talk about the use of circulating tumor DNA in oncology as a promising biomarker and an aid in tailoring individual therapy to patients. We describe what changes we can observe in ctDNA in patients with ovarian cancer and how we can use this information in diagnosis and therapy. Ovarian cancer is the deadliest of all gynecological diseases because its diagnosis and treatment still pose many problems. Surgical excision, hormone therapy, radiation, chemotherapy, or targeted therapy for eradicating the main tumor and halting the spread of metastases are among the treatment options available to individuals with ovarian cancer, depending on the disease's stage. Tumor DNA that circulates in a patient's bodily fluids has been studied recently as a possible novel biomarker for a number of cancers, as well as a means of quantifying tumor size and evaluating the efficacy of cancer therapy. The most significant alterations that we could find in the ctDNA of ovarian cancer patients—such as chromosomal instability, somatic mutations, and methylation—are discussed in this review. Additionally, we talk about the utility of ctDNA in diagnosis, prognosis, and therapy response prediction for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF